Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

BridgeBio Pharma Inc

BBIO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$79.86

▼ -1.66%

Market Cap $15.61B · Vol 822.05K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$15.61B

Large Cap

Div Yield

N/A

EPS Growth

+38.36%

YoY

RSI (14)

37.46

Momentum

Beta

0.97

vs Market

52W High

$93.31

14.41% below

52W Low

$46.82

70.59% above

Volume

822.05K

Avg 873.24K

P/B

N/A

Price-to-book

ROE

40.79%

Return on equity

Free Float

87.52%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, BridgeBio Pharma Inc (BBIO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BBIO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.47%

-5.03%

+14.64%

+6.13%

YTD

+4.41%

+56.04%

+162.18%

+59.34%

Financials & Valuation

TTM · Annual

Total Revenue	$502.08M
Net Income	$-732,938,000.00
Revenue Growth (YoY)	+120.39%
Gross Margin	95.82%
Operating Margin	-100.00%
Net Profit Margin	-145.98%
ROE	40.79%
ROA · ROIC	-78.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	29.18
P/B	N/A
P/FCF	N/A
EPS Growth	+38.36%
Outstanding Shares	195.49M

Technical Indicators

50-Day SMA	$77.19
200-Day SMA	$72.71
RSI (14)	37.46
Beta	0.97
52-Week High	$93.31
52-Week Low	$46.82

Volume Today	822.05K
Avg Daily Volume (30D)	873.24K
Relative Volume	0.94x
Volatility (10D)	25.59
Volatility (30D)	49.88
Free Float	87.52%

Analyst Consensus

BUY

Current Price $79.86

Mean Target $107.01

52W Low$46.82 52W High$93.31

Current

Target

$46.82 $93.31

Current Analyst target

+34.00% upside potential · 22 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00P9KDZL5

ISINUS10806X1028

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.